Ligand Pharmaceuticals Incorporated's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Ligand acquired XOMA Royalty, paying shareholders $39 cash plus contingent rights, expanding the company's asset base.
Ligand raised capital through convertible securities that can become up to 2.67 million shares, diluting existing shareholders.
Ligand modified its bank loan terms to allow the convertible debt issuance, showing how debt arrangements evolve.
Ligand's shareholders voted on board composition and accounting oversight, key governance decisions affecting company direction.
Ligand signed a definitive deal to acquire XOMA Royalty's royalty streams and assets, signaling strategic growth.
Ligand disclosed Q1 2026 financial results, showing how the company performed in early 2026.
Ligand publicly announced quarterly results, giving investors official financial performance information.
Stocky reads Ligand Pharmaceuticals Incorporated's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Ligand Pharmaceuticals Incorporated's most recent tracked filing was a 8-K on 14 Jul 2026: Completed merger with XOMA Royalty for thirty-nine dollars per share.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.